N,N-diethyl-4-[(3-hydroxyphenyl)[1-[(4-methylphenyl)methyl]-4-piperidinyl]amino]-benzamide | 346665-21-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N,N-diethyl-4-[(3-hydroxyphenyl)[1-[(4-methylphenyl)methyl]-4-piperidinyl]amino]-benzamide
• 英文别名: N,N-diethyl-4-(3-hydroxy-N-[1-[(4-methylphenyl)methyl]piperidin-4-yl]anilino)benzamide
• CAS: 346665-21-2
• 化学式: C₃₀H₃₇N₃O₂
• 分子量: 471.643
• InChiKey: GMVFOJKDXATNNM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  35
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  47
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  在 三溴化硼 作用下， 以 二氯甲烷 为溶剂， 生成 N,N-diethyl-4-[(3-hydroxyphenyl)[1-[(4-methylphenyl)methyl]-4-piperidinyl]amino]-benzamide
  参考文献：
  名称：

  N,N-Diethyl-4-[(3-hydroxyphenyl)(piperidin-4-yl)amino] benzamide derivatives: The development of diaryl amino piperidines as potent δ opioid receptor agonists with in vivo anti-nociceptive activity in rodent models

  摘要：

  We have investigated a series of phenolic diaryl amino piperidine delta opioid receptor agonists, establishing the importance of the phenol functional group and substitution on the piperdine nitrogen for delta agonist activity and selectivity versus the mu and kappa opioid receptors. This study uncovered compounds with improved agonist potency and selectivity compared to the standard, non-peptidic delta agonist SNC-80. In vivo anti-nociceptive activity of analog 8e in two rodent models is discussed, demonstrating the potential of delta agonists to provide a novel mechanism for pain relief. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.09.072

文献信息

• Novel compounds
  申请人：——

  公开号：US20030036552A1

  公开（公告）日：2003-02-20

  Compounds of general formula (I), R 1 is selected from any one of phenyl, pyridinyl, thiophenyl, furanyl, imidazolyl, and triazolyl; where each R 1 phenyl ring and R 1 heteroaromatic ring may optionally and independently be further substituted by 1, 2 or 3 substituents selected from straight and branched C 1 -C 6 alkyl, NO 2 , CF 3 , C 1 -C 6 alkoxy, chloro, fluoro, bromo, and iodo. The substitutions on the phenyl ring and on the heteroaromatic ring may take place in any position on said ring systems; R a and R b is each and individually selected from any one of hydrogen, a straight and branched C 1 -C 6 alkyl, NO 2 , CF 3 , C 1 -C 6 alkoxy, chloro, fluoro, bromo, and iodo; are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts and pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain.

  通式（I）的化合物，其中R1可选择自苯基、吡啶基、噻吩基、呋喃基、咪唑基和三唑基中的任意一种；其中每个R1苯环和R1杂环环可能可选地且独立地进一步被1、2或3个取代基所取代，所述取代基可选择自直链和支链的C1-C6烷基、NO2、CF3、C1-C6烷氧基、氯、氟、溴和碘。苯环和杂环上的取代作用可以发生在所述环系统的任何位置；Ra和Rb各自选择自氢、直链和支链的C1-C6烷基、 、 、C1-C6烷氧基、氯、氟、溴和碘；本申请中披露和索要了这些化合物及其药学上可接受的盐和包含这些新化合物的制药组合物，以及它们在治疗中的用途，特别是在疼痛管理中的用途。
• NOVEL COMPOUNDS
  申请人：AstraZeneca AB

  公开号：EP1242406B1

  公开（公告）日：2004-03-17
• US6875777B2
  申请人：——

  公开号：US6875777B2

  公开（公告）日：2005-04-05
• [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES
  申请人：ASTRAZENECA AB

  公开号：WO2001046263A1

  公开（公告）日：2001-06-28

  Compounds of general formula (I), R1 is selected from any one of phenyl, pyridinyl, thiophenyl, furanyl, imidazolyl, and triazolyl; where each R1 phenyl ring and R1 heteroaromatic ring may optionally and independently be further substituted by 1, 2 or 3 substituents selected from straight and branched C¿1?-C6 alkyl, NO2, CF3, C1-C6 alkoxy, chloro, fluoro, bromo, and iodo. The substitutions on the phenyl ring and on the heteroaromatic ring may take place in any position on said ring systems; R?a and Rb¿ is each and individually selected from any one of hydrogen, a straight and branched C¿1?-C6 alkyl, NO2, CF3, C1-C6 alkoxy, chloro, fluoro, bromo, and iodo; are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts and pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain.